



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 08/18/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/822,565	04/12/2004	Gunnar J. Hanson		3142
7590 08/18/2004			EXAMINER	
J. Timothy Ke		KUMAR, SHAILENDRA		
PHARMACIA CORPORATION of PFIZER INC. Global Patent Department			ART UNIT	PAPER NUMBER
P. O. Box 1027			1621	
Chesterfield, M	IO 63006			

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Symmony	10/822,565	HANSON, GUNNAR J.				
Office Action Summary	Examiner	Art Unit				
	SHAILENDRA - KUMAR	1621				
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet with th	e correspondence address				
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a incomplete the period for reply is specified above, the maximum statutory perion from the period for reply will, by state and the period for reply will, by state the provide for	N. 1.136(a). In no event, however, may a reply be reply within the statutory minimum of thirty (30) od will apply and will expire SIX (6) MONTHS fructure, cause the application to become ABANDO	e timely filed days will be considered timely. om the mailing date of this communication. NED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 12	? April 2004.					
2a) ☐ This action is FINAL . 2b) ☑ T	his action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) ⊠ Claim(s) 1-23 is/are pending in the application 4a) Of the above claim(s) is/are with defined 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 1-23 is/are rejected. 7) □ Claim(s) is/are objected to.	rawn from consideration.					
8) Claim(s) are subject to restriction and	d/or election requirement.					
Application Papers	.*					
9) ☐ The specification is objected to by the Exami	ner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the	ne drawing(s) be held in abeyance. S	See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure	ents have been received. Ints have been received in Applicationity documents have been recei	ation No				
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(c)						
Attachment(s) 1) X Notice of References Cited (PTO-892)	4) 🔲 Interview Summa	rv (PTO-413)				
 Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date 	Paper No(s)/Mail					

Application/Control Number: 10/822,565

Art Unit: 1621

DETAILED ACTION

Claims 1-23 are pending in this application.

Double Patenting

1. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

- 2. Claims 1-14 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-14 of prior U.S. Patent No. 5,414,018. This is a double patenting rejection.
- 3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 15-22 are rejected under the judicially created doctrine of obviousnesstype double patenting as being unpatentable over claims 1-7 of U.S. Patent No. Art Unit: 1621

5,488,067. Although the conflicting claims are not identical, they are not patentably distinct from each other because instant claims are directed to a method of treatment of hypertension or glaucoma, whereas the above patent is claiming treatment of hypertension only, an overlapping subject matter, using the same compounds.

- 5. Claims 15-21 and 23 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-7 of U.S. Patent No. 6,291,529. Although the conflicting claims are not identical, they are not patentably distinct from each other because instant claims are directed to a method of treatment of hypertension or glaucoma, whereas the above patent is claiming treatment of glaucoma only, an overlapping subject matter, using the same compounds.
- 6. No claim is allowed.
- Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAILENDRA KUMAR whose telephone number is (571)272-0640. The examiner can normally be reached on Mon-Thur 8:00-5:30, Alt Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on (571)272-0646. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/822,565

Art Unit: 1621

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SHAILENDRA - KUMAR Primary Examiner Art Unit 1621

S.Kumar 8/17/04